[go: up one dir, main page]

MX2010006045A - Inhibidores de transportador de glicina-1. - Google Patents

Inhibidores de transportador de glicina-1.

Info

Publication number
MX2010006045A
MX2010006045A MX2010006045A MX2010006045A MX2010006045A MX 2010006045 A MX2010006045 A MX 2010006045A MX 2010006045 A MX2010006045 A MX 2010006045A MX 2010006045 A MX2010006045 A MX 2010006045A MX 2010006045 A MX2010006045 A MX 2010006045A
Authority
MX
Mexico
Prior art keywords
inhibitors
compounds
glycine transporter
glyt
glyt1
Prior art date
Application number
MX2010006045A
Other languages
English (en)
Inventor
Wenyuan Qian
Stephen Hitchcock
Albert Amegadzie
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2010006045A publication Critical patent/MX2010006045A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos que son inhibidores del transportador de glicina 1 (en adelante referido como GlyT-1) y son por lo tanto útiles para el tratamiento de enfermedades que pueden ser tratadas por la inhibición de GlyT1 tales como trastornos cognitivos asociados con esquizofrenia, ADHD (trastorno de hiperactividad por déficit de atención), MCI (deterioro cognitivo leve) y similares. Se proporcionan también composiciones farmacéuticas que contienen estos compuestos y procedimientos para preparar los compuestos.
MX2010006045A 2007-12-12 2008-12-11 Inhibidores de transportador de glicina-1. MX2010006045A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US730607P 2007-12-12 2007-12-12
US19117908P 2008-09-05 2008-09-05
PCT/US2008/013596 WO2009075857A2 (en) 2007-12-12 2008-12-11 Glycine transporter-1 inhibitors

Publications (1)

Publication Number Publication Date
MX2010006045A true MX2010006045A (es) 2010-06-23

Family

ID=40329320

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006045A MX2010006045A (es) 2007-12-12 2008-12-11 Inhibidores de transportador de glicina-1.

Country Status (8)

Country Link
US (1) US8258306B2 (es)
EP (1) EP2231601B1 (es)
JP (2) JP2011506441A (es)
AU (1) AU2008335788B2 (es)
CA (1) CA2707305A1 (es)
ES (1) ES2486299T3 (es)
MX (1) MX2010006045A (es)
WO (1) WO2009075857A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073420A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted azetidinyl compounds as glyt1 inhibitors
EP4121031A4 (en) 2020-03-20 2024-03-27 Atux Iskay LLC 3-DIARYLMETHYLENE AND THEIR USE

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988689A (en) 1987-07-01 1991-01-29 Janssen Pharmaceutica N.V. ((Pharmacologically active bicyclic heterocyclic)methyl and -heteroatom) substituted hexahydro-1H-azepines and pyrrolidines
US5272150A (en) 1989-04-07 1993-12-21 Janssen Pharmaceutica N.V. Hydroxyalkylfuranyl derivatives
JPH05148234A (ja) 1991-10-02 1993-06-15 Hokuriku Seiyaku Co Ltd アルカン酸誘導体
EP0683767B1 (en) 1993-02-18 1998-06-03 MERCK SHARP & DOHME LTD. Azacyclic compounds, compositions containing them and their use as tachykinin antagonists
CA2255727A1 (en) 1996-05-31 1997-12-04 Trophix Pharmaceuticals, Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
US6001854A (en) 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
WO1999044596A2 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Glycine transport inhibitors
EP1135129A1 (en) 1998-12-02 2001-09-26 Novo Nordisk A/S Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
PE20001566A1 (es) 1999-03-26 2001-02-05 Ucb Sa Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
US6350761B1 (en) 1999-07-30 2002-02-26 Berlex Laboratories, Inc. Benzenamine derivatives as anti-coagulants
AU9087301A (en) 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
AU2002347906A2 (en) * 2001-10-16 2003-04-28 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
AU2002351734A1 (en) * 2001-12-20 2003-07-09 H. Lundbeck A/S Aryloxyphenlyl and arylsulfanylphenyl derivatives
AU2003288994A1 (en) * 2002-12-10 2004-06-30 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
ATE402180T1 (de) 2004-03-26 2008-08-15 Lilly Co Eli Verbindungen zur behandlung von dyslipidemie
US7807828B2 (en) 2005-08-11 2010-10-05 Hypnion, Inc. Olanzapine analogs and methods of use thereof
SI2041088T1 (sl) 2006-06-28 2014-05-30 Amgen Inc. Inhibitorji transporter-1 glicina
EP2049517B1 (en) 2006-07-20 2013-11-27 Novartis AG Amino-piperidine derivatives as cetp inhibitors

Also Published As

Publication number Publication date
WO2009075857A2 (en) 2009-06-18
EP2231601A2 (en) 2010-09-29
JP2011506441A (ja) 2011-03-03
US8258306B2 (en) 2012-09-04
US20100298341A1 (en) 2010-11-25
AU2008335788B2 (en) 2012-11-29
JP2014224146A (ja) 2014-12-04
ES2486299T3 (es) 2014-08-18
WO2009075857A3 (en) 2009-08-13
EP2231601B1 (en) 2014-06-18
CA2707305A1 (en) 2009-06-18
AU2008335788A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
MX2010006046A (es) Moduladores de gamma secretasa.
TW200612892A (en) Novel compounds
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
NO20090402L (no) Glysintransportor-1-inhibitorer
TW200407305A (en) Novel compounds
SG171690A1 (en) Treatment of protein degradation disorders
CO6382157A2 (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MX2009011090A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200745003A (en) Novel compounds
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
MX2012004548A (es) Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.
MX2009003981A (es) Agentes moduladores del receptor de calcio.
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
WO2007052023A3 (en) Novel compounds
TW200738659A (en) Novel compounds
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
UA94615C2 (uk) Інгібітори транспортера-1 гліцину
MX2007006357A (es) Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias.
MX2010006045A (es) Inhibidores de transportador de glicina-1.

Legal Events

Date Code Title Description
FG Grant or registration